Avid Bioservices Inc (CDMO)

[freethemice]

I said the September 10th PR, before the announcement of the problem with the second-line NSCLC trial.
So this staement has nothing to do with Avid's involvement, or not. Here it is

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding
Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the
future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forwardlooking
statements involve risks and uncertainties including, but not limited to, the risk that the overall survival data from the
randomized, double-blind, placebo-controlled Phase IIb together with other earlier reported data from the trial may not support
registration filings with the U.S. Food and Drug Administration, the risk that overall survival data from the planned Phase III trial
will not be consistent with the results from the randomized Phase IIb trial, the risk that results from the other randomized Phase
II trial will not be consistent with results experienced in the earlier single-arm Phase II trial or support registration filings with the
FDA, the risk that Peregrine may not have or raise adequate financial resources to complete the planned clinical programs.,
the risk that Avid's revenue growth may slow or decline, the risk that Avid may experience technical difficulties in processing
customer orders which could delay delivery of products to customers and receipt of payment, and and the risk that one or more
existing Avid customers, including those [with committed manufacturing or representing its backlog], terminates its contract prior
to completion. It is important to note that the Company's actual results could differ materially from those in any such forwardlooking
statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties
associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the
significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials;
obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for
our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying
with governmental regulations applicable to our business. Our business could be affected by a number of other factors,
including the risk factors listed from time to time in the our SEC reports including, but not limited to, the annual report on Form
10-K for the fiscal year ended April 30, 2012 and quarterly report on Form 10-Q for the quarter ended July 31, 2012. The
company cautions investors not to place undue reliance on the forward-looking statements contained in this press release.
Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking
statements in this press release.